Skip to main content

Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures

NEW YORK – Agendia and AI-based digital pathology firm Paige said today that they have entered a strategic partnership under which they will codevelop treatment planning tools that integrate Paige's cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint and BluePrint diagnostic tests.

The new combined products are intended to enable faster access to predictive and prognostic information to inform the care and treatment of breast cancer patients.

"Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue 'send out' is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia's MammaPrint and BluePrint tests will improve how we are treating breast cancer today," Agendia CEO Mark Straley said in a statement.

The companies plan to focus first on the development of digital tests for early treatment planning, where Agendia's current menu is focused. Beyond that, they also intend to use AI-derived biomarkers to advance tests for the metastatic setting.

Financial terms of the agreement were not disclosed.